Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

Zexi Hu; Yong Hu; Xicheng Liu; Rongwen Xi; Aiqun Zhang; Deruo Liu; Qiang Xie; Liang Chen

doi:10.18632/oncotarget.26252

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

PDF | How to cite

Oncotarget. 2018; 9:35283-35283. https://doi.org/10.18632/oncotarget.26252

Metrics: PDF 1349 views | ?

Zexi Hu^1,2,*, Yong Hu^1,2,*, Xicheng Liu², Rongwen Xi², Aiqun Zhang³, Deruo Liu⁴, Qiang Xie⁵ and Liang Chen^2,6

¹ College of Life Sciences, Beijing Normal University, Beijing, China
² National Institute of Biological Sciences, Beijing, China
³ The General Hospital of People’s Liberation Army (301 hospital), Beijing, China
⁴ Department of thoracic surgery, China-Japan Friendship Hospital, Beijing, China
⁵ Fuzhou Pulmonary Hospital of Fujian, Fujian, China
⁶ National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, China
^* Co-first author

Published: October 16, 2018

This article has been corrected: The correct Acknowledgment information is given below:

ACKNOWLEDGMENTS

This work was funded by National Natural Science Foundation of China grant 81472606, Chinese Ministry of Science and Technology grant (973 grant) 2011CB812401, and the Beijing Municipal Government.

Original article: Oncotarget. 2015; 6:31628-31639. DOI: https://doi.org/10.18632/oncotarget.5221.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26252

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor